

FRIDAY, JUNE 24, 2022 15:00-15:55 CET



CONTROVERSIES IN THE MANAGEMENT OF DIABETIC MACULAR EDEMA

SATURDAY, JUNE 25, 2022 13:00-14:00 CET



PEARLS AND PITFALLS IN MANAGING EXUDATIVE RETINAL DISEASE

COPHy GLOBAL VIRTUAL CONGRESS 2021

Friday 20th August 2021 15:00-16:00 CEST

FOR NON-US HEALTHCARE PROFESSIONALS ONLY

Controversies, Challenges & Evidence on the Management of DME

15:00 -15:03 Welcome and Introduction

Anat Loewenstein (Israel) - Chair

15:03 – 15:15 Expectations and fears of DME patients treated with IV injections

Audrey Giocanti (France)

15:15 – 15:27 Suitable naïve vs pre-treated DME patients

Javier Zarranz Ventura (Spain)

15:27 – 15:39 Early switch vs late switch in DME

Jorge Ruiz Medrano (Spain)

15:39 – 15:51 In the hands of the expert: what do we know about safety management?

:::: Allergan

Laurent Kodjikian (France)

15:51 – 16:00 Discussion and Q&A

Anat Loewenstein (Israel)




This symposium contains promotional material.

Symposium organised and funded by Allergan, an AbbVie company

Registration conditions and licenses differ internationally, please refer to your local Summary of Product Characteristics and Prescribing Information A list of countries with this product/ indication is available from UK_Medinfo@Allergan.com







Bayer symposium at the Virtual COPHy Global Congress 2022



Join us for a series of engaging debates as our expert speakers explore key topics in the management of exudative retinal disease

Pearls and pitfalls in managing exudative retinal disease

Saturday 25 June 2022 | 13:00-14:00 (CEST)

Chair: Dr Baruch Kuppermann

Sessions	Speaker(s)
Welcome and Introductions	Dr Baruch Kuppermann
Is proactive individualised treatment the new standard of care in DME?	Yes : Dr John Kitchens No : Professor Gemmy Cheung
Is real-world experience as important as the pivotal studies in determining a drug's use?	Yes: Mr James Talks No: Dr Patricia Udaondo
Have we arrived at the end of the road for advancements in nAMD treatment?	Yes: Dr Stela Vujosevic No: Dr Aude Ambresin
Live: Panel discussion / audience Q&A	All
Summary of key learnings	Dr Baruch Kuppermann

Learn more about Bayer by visiting our online channels:



COPHy, Controversies in Ophthalmology. DME, diabetic macular oedema. nAMD, neovascular age-related macular degeneration.

This symposium is organised and supported by Bayer.

The summary of product characteristics (SmPC) of affibercept solution for injection as approved by the European Commission for the European Union can be found https://example.com/html/percept-solution-representative.

May 2022 | PP-EYL-ALL-0950-1

